Sein métastatique RH+ HerSeq (PUMA-NER-9501) HER-Seq: A Blood-based Screening Study to Identify Patients with HER2 Mutations for;Enrollment into Clinical Research Studies of Neratinib Paris, Saint-Cloud
VADS ICING ORL A Phase II Trial Assessing Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-ß and PD-L1, in a Pre-operative Setting for Resectable and Untreated Head and Neck Squamous Cell Carcinoma Paris CHRISTOPHE LE TOURNEAU, CHRISTOPHE LE TOURNEAU
VADS INDUCE-3 (GSK-209229) Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3) Paris CHRISTOPHE LE TOURNEAU
VADS INDUCE-4 (GSK-209227) A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Paris CHRISTOPHE LE TOURNEAU
Pédiatrie Tumeurs solides I3Y-MC-JPCS JPCS(2.1) Clinical Protocol Addendum Page 1;LY2835219;1. Protocol Addendum I3Y-MC-JPCS(2.1);A Phase 1b Dose Escalation Study of Abemaciclib in;Combination with Temozolomide and Irinotecan (Part A);and Abemaciclib in Combination with Temozolomide;(Part B) in Pediatric and Young Adult Patients with;Relapsed/Refractory Solid Tumors Paris ISABELLE AERTS
Sein métastatique RH+ PALATINE - UC-0140/1814 ADVANCED BREAST CANCER: THERAPY INTEGRATING LOCOREGIONAL TREATMENT IN DE NOVO,;TREATMENT NAIVE, STAGE IV ER+, HER2- BREAST CANCER PATIENTS RECEIVING LETROZOLE AND;PALBOCICLIB Paris, Saint-Cloud
Gynécologie - Ovaires TG4050.01 A phase I trial evaluating a mutanome-directed immunotherapy in patients with high grade serous carcinoma (HGSC) of the ovary, fallopian tube or peritoneum who experience an asymptomatic relapse Paris CHRISTOPHE LE TOURNEAU
VADS TrilynX (Debio 1143-SCCHN-301) A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in;combination with platinum-based chemotherapy and standard fractionation intensitymodulated;radiotherapy in patients with locally advanced squamous cell carcinoma of;the head and neck, suitable for definitive chemoradiotherapy (TrilynX). Paris CHRISTOPHE LE TOURNEAU
Sein métastatique RH+ DESTINY-Breast06 (D9670C00001) A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator·s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) Paris, Saint-Cloud JEAN-YVES PIERGA, ETIENNE BRAIN
VADS M19-894 A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability,;Pharmacokinetics, and Preliminary Efficacy of ABBV-368 plus Tilsotolimod and Other Therapy;Combinations in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Paris CHRISTOPHE LE TOURNEAU